Te Arai Health
Preservation Society

S proprietary ddRNAi technology.

Benitec provides appointed Mr. Bob Atwill, Senior Vice President Cellular Therapies, to advance this and additional potential possibilities in cellular and immunotherapies, such as for example ddRNAi-modified CAR-T cells. Mr Atwill offers extensive encounter in the stem cell sector and was the previous CEO of the Regenerative Medication Division of Allied Health care Group, now Admedus.. Benitec, ReNeuron collaborate to start brand-new exploratory cellular therapy program Benitec Biopharma is very happy to announce the release of a fresh exploratory cellular therapy plan including exosome-based delivery using the Firm's proprietary ddRNAi technology.The methodology included in this allowance covers multispectral imaging equipment and algorithm-based approaches broadly, including the usage of CRi’s patented liquid crystal tunable filtration system technology and CRi’s picture acquisition and data evaluation software programs. ‘We are pleased to see reputation from the US Patent office for this fundamental patent that teaches quantitative multispectral image evaluation of fluorescent samples in living mammals,’ says Peter Miller, Vice President and Chief Science Officer at CRi.